And what a hefty price for non-FDA endorsed trials, IHL shareholders will see a 22% dilution as they'll grant Cannvalate 120 millions options, - currently total shares are about 550 millions.
And what a hefty price for non-FDA endorsed trials, IHL...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
0.008(2.38%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $624.4K | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 440962 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 515755 | 15 |
View Market Depth
| Last trade - 13.40pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
